ValuEngine upgraded shares of Protalex Inc. (OTCMKTS:PRTX) from a strong sell rating to a sell rating in a research note issued to investors on Wednesday.

Protalex (OTCMKTS PRTX) opened at 1.00 on Wednesday. Protalex has a 12 month low of $0.31 and a 12 month high of $3.00. The firm’s 50-day moving average is $0.67 and its 200 day moving average is $0.84. The firm’s market capitalization is $28.77 million.

ILLEGAL ACTIVITY NOTICE: This report was first published by The Cerbat Gem and is owned by of The Cerbat Gem. If you are accessing this report on another website, it was illegally copied and reposted in violation of international trademark & copyright legislation. The original version of this report can be read at

About Protalex

Protalex, Inc is a clinical-stage company. The Company is focused on the development of a class of biopharmaceutical drugs for treating autoimmune and inflammatory diseases, including rheumatoid arthritis (RA) and Immune Thrombocytopenia (ITP). The Company’s lead product candidate, PRTX-100, is a formulation of the Staphylococcal bacterial protein known as Protein A, which modifies aspects of the human immune system.

To view ValuEngine’s full report, visit ValuEngine’s official website.

Receive News & Stock Ratings for Protalex Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Protalex Inc. and related stocks with our FREE daily email newsletter.